Page 4 - Alkermes News Today

Alkermes (NASDAQ:ALKS – Get Free Report) will issue its quarterly earnings data before the market opens on Wednesday, May 1st. Analysts expect the company to announce earnings of $0.61 per share for the quarter. Parties that wish to register for the company’s conference call can do so using this link. Alkermes (NASDAQ:ALKS – Get Free […]

AN EXPERIENCED pharmaceutical industry leader has been appointed as Director of the Pharmaceutical Manufacturing Technology Centre at UL.

HRMY earnings call for the period ending March 31, 2024.

The phase 2 trial will evaluate the safety and efficacy of ALKS 2680, a novel orexin-2 receptor agonist, in patients with narcolepsy type 1.

Alkermes plc (Nasdaq: ALKS) today announced initiation of the Vibrance-1 study, a phase 2 clinical trial evaluating the safety and efficacy of ALKS 2680 compared to placebo in patients with narcolepsy type 1 (NT1). ALKS 2680 is the company's novel, investigational, oral orexin 2 receptor (OX2R) agonist in development as a once-daily treatment for narcolepsy, a chronic, neurological disorder characterized by excessive daytime sleepiness. NT1 is associated with an absence or significant defic...

Alkermes plc (NASDAQ:ALKS – Free Report) – Analysts at Zacks Research lifted their Q3 2025 earnings per share estimates for Alkermes in a report released on Wednesday, April 10th. Zacks Research analyst R. Department now anticipates that the company will post earnings per share of $0.52 for the quarter, up from their prior estimate of […]

Alkermes plc (NASDAQ:ALKS – Free Report) – Equities researchers at Leerink Partnrs reduced their FY2027 earnings estimates for Alkermes in a research report issued on Tuesday, April 9th. Leerink Partnrs analyst M. Goodman now expects that the company will post earnings per share of $1.35 for the year, down from their prior estimate of $1.45. […]

A closer look at one of the leaders in the global bipolar disorder treatment market

Alkermes plc (NASDAQ:ALKS – Free Report) – Research analysts at Leerink Partnrs dropped their FY2027 earnings per share (EPS) estimates for shares of Alkermes in a research note issued to investors on Tuesday, April 9th. Leerink Partnrs analyst M. Goodman now expects that the company will post earnings per share of $1.35 for the year, […]

Alkermes plc announced positive results from a phase 1b study evaluating ALKS 2680 for treating narcolepsy type 2 and idiopathic hypersomnia.